Radius Health, Inc. (RDUS): Price and Financial Metrics

Radius Health, Inc. (RDUS): $16.53

-1.14 (-6.45%)

POWR Rating

Component Grades














  • Value is the dimension where RDUS ranks best; there it ranks ahead of 85.85% of US stocks.
  • The strongest trend for RDUS is in Momentum, which has been heading down over the past 52 weeks.
  • RDUS's current lowest rank is in the Sentiment metric (where it is better than 1.84% of US stocks).

RDUS Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for RDUS is -0.94 -- better than just 4.36% of US stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at -0.96 for Radius Health Inc; that's greater than it is for merely 4.94% of US stocks.
  • With a year-over-year growth in debt of 50.78%, Radius Health Inc's debt growth rate surpasses 85.67% of about US stocks.
  • If you're looking for stocks that are quantitatively similar to Radius Health Inc, a group of peers worth examining would be INSM, FBIO, CLVS, OMER, and AKBA.
  • RDUS's SEC filings can be seen here. And to visit Radius Health Inc's official web site, go to www.radiuspharm.com.

RDUS Valuation Summary

  • In comparison to the median Healthcare stock, RDUS's EV/EBIT ratio is 183.28% lower, now standing at -24.4.
  • RDUS's price/earnings ratio has moved down 10.9 over the prior 88 months.
  • Over the past 88 months, RDUS's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for RDUS.

Stock Date P/S P/B P/E EV/EBIT
RDUS 2021-08-31 2.6 -2.9 -10.9 -24.4
RDUS 2021-08-30 2.6 -2.8 -10.7 -24.1
RDUS 2021-08-27 2.6 -2.8 -10.7 -24.1
RDUS 2021-08-26 2.5 -2.8 -10.4 -23.6
RDUS 2021-08-25 2.6 -2.8 -10.6 -23.9
RDUS 2021-08-24 2.6 -2.8 -10.7 -24.1

RDUS Growth Metrics

  • Its 2 year net cashflow from operations growth rate is now at 63.8%.
  • Its 2 year net income to common stockholders growth rate is now at 50.59%.
  • Its 2 year revenue growth rate is now at 422.1%.
Over the past 33 months, RDUS's revenue has gone up $128,412,000.

The table below shows RDUS's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-09-30 227.651 -51.543 -75.977
2021-06-30 248.667 -61.983 -60.233
2021-03-31 246.983 -59.876 -87.303
2020-12-31 238.645 -73.948 -109.208
2020-09-30 231.527 -54.003 -112.538
2020-06-30 200.467 -74.765 -136.293

RDUS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • RDUS has a Quality Grade of C, ranking ahead of 69.93% of graded US stocks.
  • RDUS's asset turnover comes in at 1.266 -- ranking 15th of 682 Pharmaceutical Products stocks.
  • FOLD, ADMS, and CSBR are the stocks whose asset turnover ratios are most correlated with RDUS.

The table below shows RDUS's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 1.266 0.929 -0.122
2021-03-31 1.287 0.930 -0.218
2020-12-31 1.249 0.928 -0.297
2020-09-30 1.170 0.926 -0.307
2020-06-30 0.974 0.914 -0.387
2020-03-31 0.858 0.912 -0.347

RDUS Price Target

For more insight on analysts targets of RDUS, see our RDUS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $22.14 Average Broker Recommendation 1.93 (Hold)

RDUS Stock Price Chart Interactive Chart >

Price chart for RDUS

RDUS Price/Volume Stats

Current price $16.53 52-week high $26.16
Prev. close $17.67 52-week low $11.95
Day low $16.22 Volume 348,500
Day high $17.70 Avg. volume 672,870
50-day MA $16.75 Dividend yield N/A
200-day MA $17.89 Market Cap 782.56M

Radius Health, Inc. (RDUS) Company Bio

Radius Health is a biopharmaceutical company focused on developing new therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases including hormone responsive metastatic breast cancer. The company was founded in 2003 and is based in Waltham, Massachusetts.

RDUS Latest News Stream

Event/Time News Detail
Loading, please wait...

RDUS Latest Social Stream

Loading social stream, please wait...

View Full RDUS Social Stream

Latest RDUS News From Around the Web

Below are the latest news stories about Radius Health Inc that investors may wish to consider to help them evaluate RDUS as an investment opportunity.

These 40 Mass. companies made the new Deloitte Fast 500 list

The list, released Wednesday, ranks the fastest-growing technology, media, telecommunications and life sciences companies based in North America.

Yahoo | November 17, 2021

Zacks: Analysts Expect Radius Health, Inc. (NASDAQ:RDUS) Will Announce Quarterly Sales of $63.10 Million

Wall Street brokerages expect Radius Health, Inc. (NASDAQ:RDUS) to post $63.10 million in sales for the current fiscal quarter, Zacks reports. Five analysts have made estimates for Radius Healths earnings, with the highest sales estimate coming in at $68.94 million and the lowest estimate coming in at $60.90 million. Radius Health reported sales of $62.78 []

Dakota Financial News | November 15, 2021

Radius Health (NASDAQ:RDUS) Price Target Lowered to $23.00 at HC Wainwright

Radius Health (NASDAQ:RDUS) had its price objective cut by HC Wainwright from $26.00 to $23.00 in a report released on Tuesday morning, The Fly reports. They currently have a neutral rating on the biopharmaceutical companys stock. Other research analysts also recently issued reports about the stock. SVB Leerink boosted their price objective on shares of []

Dakota Financial News | November 13, 2021

Radius Health (NASDAQ:RDUS) Price Target Raised to $30.00

Radius Health (NASDAQ:RDUS) had its price objective raised by SVB Leerink from $29.00 to $30.00 in a report published on Tuesday, PriceTargets.com reports. SVB Leerink currently has a market perform rating on the biopharmaceutical companys stock. A number of other equities analysts have also recently issued reports on the stock. HC Wainwright reduced their price []

Dakota Financial News | November 12, 2021

HC Wainwright Lowers Radius Health (NASDAQ:RDUS) Price Target to $23.00

Radius Health (NASDAQ:RDUS) had its target price lowered by stock analysts at HC Wainwright from $26.00 to $23.00 in a research report issued on Tuesday, The Fly reports. The brokerage presently has a neutral rating on the biopharmaceutical companys stock. HC Wainwrights price objective would suggest a potential upside of 24.93% from the companys current []

Transcript Daily | November 11, 2021

Read More 'RDUS' Stories Here

RDUS Price Returns

1-mo -25.91%
3-mo 21.01%
6-mo N/A
1-year 2.80%
3-year 4.69%
5-year -68.00%
YTD -7.45%
2020 -11.41%
2019 22.26%
2018 -48.10%
2017 -16.46%
2016 -38.20%

Continue Researching RDUS

Want to see what other sources are saying about Radius Health Inc's financials and stock price? Try the links below:

Radius Health Inc (RDUS) Stock Price | Nasdaq
Radius Health Inc (RDUS) Stock Quote, History and News - Yahoo Finance
Radius Health Inc (RDUS) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 1.0259 seconds.